SCHEMBL370806

SCHEMBL370806

CCCCCCCCCCCCCCCCOC(P)C(CO)OCCCCCCCCCCCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
MGAM O43451 3/20 0.42
DNM1 Q05193 1/20 0.41
CNR2 P34972 3/20 0.41
ALDH1A1 P00352 1/20 0.41
CNR1 P21554 1/20 0.41
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
LMNA P02545 1/20 0.38
GBA1 P04062 1/20 0.37
LPAR6 P43657 1/20 0.36
LPAR1 Q92633 1/20 0.36
LPAR4 Q99677 1/20 0.36
LPAR5 Q9H1C0 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36
LPAR3 Q9UBY5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29169801 0.86 USP2 (0.50) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL371177 0.81 MAPT (0.55) DNM1ALDH1A1MEN1KMT2AMAPT
SCHEMBL29169842 0.80 USP2 (0.50) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL10466712 0.78 MGAM (0.52) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL4288378 0.78 LMNA (0.48) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL27592379 0.78 MGAM (0.52) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL17792592 0.77 TSHR (0.44) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL8630707 0.76 CYP2D6 (0.52) USP2MGAMCNR2ALDH1A1CNR1
SCHEMBL28381666 0.74 MEN1 (0.41) USP2MGAMDNM1CNR2ALDH1A1
SCHEMBL29169777 0.74 USP2 (0.62) USP2MGAMMEN1THRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384612-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION Mirnagreen S.r.l. (IT) 2024-06-19 EP disclosed
CN-111867634-B Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers 阿尔吉法玛公司 2024-06-11 CN disclosed
CN-117940563-A Improved small RNA purification process 米尔纳格林有限责任公司 2024-04-26 CN disclosed
WO-2023017116-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION MIRNAGREEN S.R.L. (IT) 2023-02-16 WO disclosed
EP-4134432-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION Mirnagreen S.r.l. (IT) 2023-02-15 EP disclosed
CN-114729336-A Cell-free composition for ATP regeneration and use thereof 百奥堪引赛股份有限公司 2022-07-08 CN disclosed
US-20220204967-A1 METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS MIRNAGREEN S.R.L. (IT) 2022-06-30 US disclosed
US-20220145282-A1 Cell-Free Compositions for ATP Regeneration and Uses Thereof BIOCHEMINSIGHTS, INC. 2022-05-12 US disclosed
EP-3924471-A1 CELL-FREE COMPOSITIONS FOR ATP REGENERATION AND USES THEREOF Biocheminsights Inc. (US) 2021-12-22 EP disclosed
EP-3901259-A1 METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS Mirnagreen S.r.l. (IT) 2021-10-27 EP disclosed
US-20130251630-A1 Entrapment of Radionuclides in Nanoparticle Compositions RIGSHOSPITALET (DK) 2013-09-26 US disclosed
WO-2013135800-A1 CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD BIONEER A/S (DK) 2013-09-19 WO disclosed
EP-2638896-A1 Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood Bioneer A/S (DK) 2013-09-18 EP disclosed
US-20130204121-A1 NANOPARTICLE-GUIDED RADIOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2013-08-08 US disclosed
EP-2593186-A1 NANOPARTICLE-GUIDED RADIOTHERAPY Technical University of Denmark (DK) 2013-05-22 EP disclosed
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES RIGSHOSPITALET (DK) 2012-08-23 US disclosed
WO-2012079582-A1 ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS TECHNICAL UNIVERSITY OF DENMARK (DK) 2012-06-21 WO disclosed
EP-2453927-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES Technical University of Denmark (DK) 2012-05-23 EP disclosed
WO-2012007567-A1 NANOPARTICLE-GUIDED RADIOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2012-01-19 WO disclosed
WO-2011006510-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES TECHNICAL UNIVERSITY OF DENMARK (DK) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES LIPG, NPC1L1, CD47 USP2 2736/4885MGAM 3352/4885DNM1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.